Kineta Unveils New Data From VISTA-101 Clinical Trial Of KVA12123 At The Society For Immunotherapy Of Cancer's 38th Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Kineta, Inc. (NASDAQ:KA) has presented positive data from its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123, its VISTA blocking immunotherapy, in patients with advanced solid tumors. The data shows excellent safety and tolerability, with no evidence of CRS-associated Cytokines. The pharmacokinetic data and biomarker assessments demonstrate the drug's potential efficacy and confirm its mechanism of action. Additional monotherapy and combination therapy clinical data are anticipated in Q2 2024.
November 06, 2023 | 1:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Kineta's positive clinical trial data for KVA12123 indicates potential efficacy in treating advanced solid tumors, which could boost investor confidence and potentially impact the company's stock positively in the short term.
The positive clinical trial data for Kineta's KVA12123 indicates the drug's potential efficacy in treating advanced solid tumors. This could boost investor confidence in the company's ability to develop effective treatments, potentially leading to increased demand for the company's stock and a rise in its price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100